Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pharvaris (PHVS)
NASDAQ:PHVS
Pharvaris (PHVS) Stock Price & Analysis
62 Followers
PHVS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.20 - $33.00
Previous Close$20.35
Volume33.05K
Average Volume (3M)70.57K
Market Cap
$1.10B
Enterprise Value$672.03M
Total Cash (Recent Filing)€391.23M
Total Debt (Recent Filing)€238.91K
Price to Earnings (P/E)-7.5
Beta-1.55
Next Earnings
Jul 26, 2024EPS Estimate
-$0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.71
Shares Outstanding52,290,212
10 Day Avg. Volume36,754
30 Day Avg. Volume70,567
Standard Deviation0.75
R-Squared0.04
Alpha0.12
Financial Highlights & Ratios
Price to Book (P/B)2.96
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$36.60Price Target Upside79.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Pharvaris News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPharvaris is progressing with its pivotal prophylactic and acute HAE programs, indicating strong management execution.
Regulatory MilestoneAn EOP2 meeting with the FDA is scheduled to discuss the prophylactic opportunity, showing regulatory advancement.
Stock ValuationAnalysts believe the market is currently underappreciating the acute HAE opportunity, suggesting room for growth in the stock's valuation.
Bears Say
Clinical Trial ConcernsInvestors are cautious due to the ongoing clinical hold, which needs to be resolved before deucrictibant can receive full credit for the CHAPTER-1 data.
Competitive LandscapePotential volatility in PHVS shares expected with competitor's trial data release, highlighting market sensitivity to competitive developments.
Drug Efficacy DoubtsSome inconsistencies in the data suggest that while sebetralstat is effective, a significant portion of patients required a second dose, and not all attacks were resolved within 24 hours.
---
Ownership Overview
0.00%
Insiders
7.32% Mutual Funds
66.42% Other Institutional Investors
26.26% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PHVS FAQ
What was Pharvaris’s price range in the past 12 months?
Pharvaris lowest stock price was $8.20 and its highest was $33.00 in the past 12 months.
What is Pharvaris’s market cap?
Currently, no data Available
When is Pharvaris’s upcoming earnings report date?
Pharvaris’s upcoming earnings report date is Jul 26, 2024 which is in 69 days.
How were Pharvaris’s earnings last quarter?
Currently, no data Available
Is Pharvaris overvalued?
According to Wall Street analysts Pharvaris’s price is currently Undervalued.
Does Pharvaris pay dividends?
Pharvaris does not currently pay dividends.
What is Pharvaris’s EPS estimate?
Pharvaris’s EPS estimate is -$0.6.
How many shares outstanding does Pharvaris have?
Pharvaris has 53,816,708 shares outstanding.
What happened to Pharvaris’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pharvaris?
Among the largest hedge funds holding Pharvaris’s share is Viking Global Investors LP. It holds Pharvaris’s shares valued at 103M.
---
Pharvaris Stock Smart Score
Company Description
Pharvaris
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
---
PHVS Stock 12 Month Forecast
Average Price Target
$36.60
▲(79.85% Upside)
Technical Analysis
Best Analysts Covering PHVS
1 Year
1 Year Success Rate
12/17 ratings generated profit
1 Year Average Return
+79.21%
reiterated a buy rating 10 days ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +79.21% per trade.
---